Chemours Company (The) (CC) Earning Positive Media Coverage, Study Finds

Claudine Rigal
Juillet 17, 2017

A number of research analysts have recently weighed in on the company. Citigroup Inc. reaffirmed a "neutral" rating and issued a $40.00 price target (up previously from $34.00) on shares of Chemours Company (The) in a research report on Friday, April 14th. 1 is equivalent to a buy rating, 3 a hold rating, and 5 a sell rating. Zacks Investment Research raised Chemours Company (The) from a "hold" rating to a "strong-buy" rating and set a $38.00 price target for the company in a report on Thursday, February 16th. J P Morgan Chase & Co raised Chemours Company (The) from a "neutral" rating to an "overweight" rating and lifted their price objective for the company from $39.00 to $50.00 in a research note on Friday, May 12th. Jefferies Group LLC raised Chemours Company (The) from a "hold" rating to a "buy" rating and lifted their price objective for the company from $35.00 to $48.00 in a research note on Wednesday, March 29th. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock.

Chemours Company (NYSE:CC) opened at 44.76 on Friday.

ATR value of company was 1.74. The Chemours Company (NYSE:CC) notched a 12-month high of $43.75 while $55.00 target is by far the most aggressive out of analysts who are now evaluating CC, $11.25 higher than the next highest 52-week price estimate. The stock has a market cap of $8.26 billion, a price-to-earnings ratio of 78.25 and a beta of 3.57. The Stock becomes significant when you consider how many shares are shorted versus the average daily volume, means how many days to cover those short shares at that volume.

Last time, the company shocked Wall Street by reporting EPS of $0.75, smashing the consensus of $0.50 per share.

4 number of analysts have estimated the sales of the company for the quarter, analysts estimated mean sale target of 1442.03 million while high and low sale targets are estimated at 1495.41 million and 1399 million respectively.

Talking about profitability of the company, the profit margin percentage is 1.91% while its operating margin for the trailing twelve month is at 10.74%.

Over the last 5 years, The Chemours Company has averaged a -65.60% YoY EPS growth rate and a -7.50% revenue growth rate. During the same quarter in the previous year, the firm posted $0.06 EPS. On average, equities analysts anticipate that Chemours Company will post $3.31 EPS for the current fiscal year.

Additionally the company announced a dividend paid on Thursday the 15th of June 2017. Shareholders of record on Wednesday, May 17th were given a dividend of $0.03 per share. The dividend yield was $0.29. Susquehanna Bancshares Inc increased their target price on shares of Chemours Company (The) from $45.00 to $55.00 and gave the company a positive rating in a report on Monday, May 15th.

Let's have a look at some of the important valuation ratios of the Chemours Company (The) (CC). Norges Bank purchased a new position in shares of Chemours Company (The) during the fourth quarter worth $196,709,000. If you are accessing this piece on another website, it was illegally copied and reposted in violation of global trademark & copyright legislation. The legal version of this report can be viewed at https://www.com-unik.info/2017/07/13/chemours-company-the-cc-upgraded-by-bidaskclub-to-buy.html.

In other news, VP Mark Newman sold 22,781 shares of the firm's stock in a transaction that occurred on Friday, May 5th. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The shares were acquired at an average price of $39.10 per share, for a total transaction of $97,750.00. The disclosure for this purchase can be found here.

News articles about Chemours Company (The) (NYSE:CC) have trended positive recently, Accern Sentiment reports. Cypress Capital Management LLC WY now owns 4,196 shares of the specialty chemicals company's stock worth $162,000 after buying an additional 80 shares during the last quarter. Charter Trust Co. increased its stake in Chemours Company (The) by 2.1% in the second quarter. The average volume stands around 3.07 million shares. Cypress Capital Management LLC WY raised its position in Chemours Company (The) by 1.9% in the first quarter. The institutional investor owned 13,400 shares of the specialty chemicals company's stock at the end of the first quarter. Finally, United Capital Financial Advisers LLC bought a new position in shares of Chemours Company (The) during the first quarter worth $203,000.

D'autres rapports CampDesrEcrues

Discuter de cet article

SUIVRE NOTRE JOURNAL